GEE-SUE PARK: Open Payments
NPI 1467078121 · LANGHORNE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,143 in 90 payments from 17 companies in 2025. Trend: 2023 $294 · 2024 $1,991 · 2025 $2,143
Food & beverage: $2,143
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $255 |
| Madrigal Pharmaceuticals | 8 | $211 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $203 |
| Ardelyx, Inc. | 4 | $196 |
| Braintree Laboratories, Inc. | 5 | $188 |
| Lilly USA, LLC | 5 | $112 |
| Janssen Biotech, Inc. | 4 | $112 |
| PFIZER INC. | 6 | $108 |
| QOL Medical, LLC | 3 | $82 |
Products named: ENTYVIO, REZDIFFRA, XIFAXAN, IBSRELA, SUFLAVE, TREMFYA, LINZESS, XELJANZ.
Industry payments across PA — which companies pay providers there.
